CYP2B6
Summary: This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide. Transcript variants for this gene have been described; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely related pseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| cytochrome P450 family 2 subfamily B member 6 | MIM:123930 | Ensembl:ENSG00000197408 | HGNC:HGNC:2615 | PA123 | 19q13.2 |
GO terms in CYP2B6
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IDA | GO:0004497 | monooxygenase activity |
| MF | TAS | GO:0004497 | monooxygenase activity |
| MF | IEA | GO:0005506 | iron ion binding |
| MF | IBA | GO:0008392 | arachidonic acid epoxygenase activity |
| MF | IBA | GO:0008395 | steroid hydroxylase activity |
| MF | IBA | GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen |
| MF | IEA | GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen |
| MF | IBA | GO:0020037 | heme binding |
| MF | IDA | GO:0020037 | heme binding |
| BP | IBA | GO:0006082 | organic acid metabolic process |
| BP | IBA | GO:0006805 | xenobiotic metabolic process |
| BP | IDA | GO:0006805 | xenobiotic metabolic process |
| BP | TAS | GO:0006805 | xenobiotic metabolic process |
| BP | IMP | GO:0008202 | steroid metabolic process |
| BP | IDA | GO:0017144 | drug metabolic process |
| BP | IMP | GO:0017144 | drug metabolic process |
| BP | IDA | GO:0042180 | cellular ketone metabolic process |
| BP | IBA | GO:0042738 | exogenous drug catabolic process |
| BP | IDA | GO:0042738 | exogenous drug catabolic process |
| BP | IBA | GO:0055114 | oxidation-reduction process |
| BP | IDA | GO:0055114 | oxidation-reduction process |
| CC | IBA | GO:0005737 | cytoplasm |
| CC | TAS | GO:0005789 | endoplasmic reticulum membrane |
| CC | IEA | GO:0031090 | organelle membrane |
| CC | IBA | GO:0043231 | intracellular membrane-bounded organelle |
Gene expression in normal tissue: CYP2B6
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in CYP2B6
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| wikipathways | WP1600 | Nicotine Metabolism |
| wikipathways | WP2874 | Liver X Receptor Pathway |
| wikipathways | WP2875 | Constitutive Androstane Receptor Pathway |
| wikipathways | WP2876 | Pregnane X Receptor pathway |
| wikipathways | WP2877 | Vitamin D Receptor Pathway |
| wikipathways | WP2882 | Nuclear Receptors Meta-Pathway |
| wikipathways | WP299 | Nuclear Receptors in Lipid Metabolism and Toxicity |
| wikipathways | WP3871 | Valproic acid pathway |
| wikipathways | WP3915 | Angiopoietin Like Protein 8 Regulatory Pathway |
| wikipathways | WP4010 | Liver steatosis AOP |
| wikipathways | WP43 | Oxidation by Cytochrome P450 |
| wikipathways | WP702 | Metapathway biotransformation Phase I and II |
| smpdb | SMP00074 | Retinol Metabolism |
| smpdb | SMP00075 | Arachidonic Acid Metabolism |
| smpdb | SMP00077 | Piroxicam Action Pathway |
| smpdb | SMP00083 | Acetylsalicylic Acid Action Pathway |
| smpdb | SMP00084 | Etodolac Action Pathway |
| smpdb | SMP00085 | Ketoprofen Action Pathway |
| smpdb | SMP00086 | Ibuprofen Action Pathway |
| smpdb | SMP00087 | Rofecoxib Action Pathway |
| smpdb | SMP00093 | Diclofenac Action Pathway |
| smpdb | SMP00094 | Sulindac Action Pathway |
| smpdb | SMP00096 | Celecoxib Action Pathway |
| smpdb | SMP00098 | Ketorolac Action Pathway |
| smpdb | SMP00101 | Suprofen Action Pathway |
| smpdb | SMP00102 | Bromfenac Action Pathway |
| smpdb | SMP00104 | Indomethacin Action Pathway |
| smpdb | SMP00106 | Meloxicam Action Pathway |
| smpdb | SMP00109 | Mefenamic Acid Action Pathway |
| smpdb | SMP00113 | Oxaprozin Action Pathway |
| smpdb | SMP00114 | Nabumetone Action Pathway |
| smpdb | SMP00116 | Valdecoxib Action Pathway |
| smpdb | SMP00120 | Naproxen Action Pathway |
| smpdb | SMP00260 | Clopidogrel Action Pathway |
| smpdb | SMP00289 | Diflunisal Action Pathway |
| smpdb | SMP00336 | Vitamin A Deficiency |
| smpdb | SMP00353 | Leukotriene C4 Synthesis Deficiency |
| smpdb | SMP00408 | Methadone Action Pathway |
| smpdb | SMP00431 | Nicotine Action Pathway |
| smpdb | SMP00447 | Cyclophosphamide Action Pathway |
| smpdb | SMP00448 | Ifosfamide Action Pathway |
| smpdb | SMP00471 | Tamoxifen Action Pathway |
| smpdb | SMP00604 | Cyclophosphamide Metabolism Pathway |
| smpdb | SMP00605 | Ifosfamide Metabolism Pathway |
| smpdb | SMP00606 | Tamoxifen Metabolism Pathway |
| smpdb | SMP00610 | Clopidogrel Metabolism Pathway |
| smpdb | SMP00624 | Methadone Metabolism Pathway |
| smpdb | SMP00628 | Nicotine Metabolism Pathway |
| smpdb | SMP00634 | Carbamazepine Metabolism Pathway |
| smpdb | SMP00635 | Valproic Acid Metabolism Pathway |
| smpdb | SMP00637 | Tramadol Metabolism Pathway |
| smpdb | SMP00642 | Nevirapine Metabolism Pathway |
| smpdb | SMP00648 | Sorafenib Metabolism Pathway |
| smpdb | SMP00692 | Antipyrine Action Pathway |
| smpdb | SMP00693 | Antrafenine Action Pathway |
| smpdb | SMP00694 | Carprofen Action Pathway |
| smpdb | SMP00695 | Etoricoxib Action Pathway |
| smpdb | SMP00696 | Fenoprofen Action Pathway |
| smpdb | SMP00697 | Flurbiprofen Action Pathway |
| smpdb | SMP00698 | Magnesium salicylate Action Pathway |
| smpdb | SMP00699 | Lumiracoxib Action Pathway |
| smpdb | SMP00700 | Lornoxicam Action Pathway |
| smpdb | SMP00701 | Phenylbutazone Action Pathway |
| smpdb | SMP00702 | Nepafenac Action Pathway |
| smpdb | SMP00703 | Trisalicylate-choline Action Pathway |
| smpdb | SMP00704 | Tolmetin Action Pathway |
| smpdb | SMP00705 | Tiaprofenic Acid Action Pathway |
| smpdb | SMP00706 | Tenoxicam Action Pathway |
| smpdb | SMP00707 | Salsalate Action Pathway |
| smpdb | SMP00708 | Salicylate-sodium Action Pathway |
| smpdb | SMP00709 | Salicylic Acid Action Pathway |
| smpdb | SMP00710 | Acetaminophen Action Pathway |
| humancyc | PWY66-241 | bupropion degradation |
| pharmgkb | PA145011115 | Phenytoin Pathway, Pharmacokinetics |
| pharmgkb | PA145011119 | Tamoxifen Pathway, Pharmacokinetics |
| pharmgkb | PA154424674 | Clopidogrel Pathway, Pharmacokinetics |
| pharmgkb | PA165378192 | Artemisinin and Derivatives Pathway, Pharmacokinetics |
| pharmgkb | PA165817070 | Carbamazepine Pathway, Pharmacokinetics |
| pharmgkb | PA165946349 | Tramadol Pharmacokinetics |
| pharmgkb | PA165950411 | Nevirapine Pathway, Pharmacokinetics |
| pharmgkb | PA165959537 | Sorafenib Pharmacokinetics |
| pharmgkb | PA165964265 | Valproic Acid Pathway, Pharmacokinetics |
| pharmgkb | PA2011 | Nicotine Pathway, Pharmacokinetics |
| pharmgkb | PA2034 | Cyclophosphamide Pathway, Pharmacokinetics |
| pharmgkb | PA2037 | Ifosfamide Pathway, Pharmacokinetics |
| kegg | hsa00590 | Arachidonic acid metabolism - Homo sapiens (human) |
| kegg | hsa00830 | Retinol metabolism - Homo sapiens (human) |
| kegg | hsa00980 | Metabolism of xenobiotics by cytochrome P450 - Homo sapiens (human) |
| kegg | hsa00982 | Drug metabolism - cytochrome P450 - Homo sapiens (human) |
| reactome | R-HSA-1430728 | Metabolism |
| reactome | R-HSA-211859 | Biological oxidations |
| reactome | R-HSA-211897 | Cytochrome P450 - arranged by substrate type |
| reactome | R-HSA-211935 | Fatty acids |
| reactome | R-HSA-211945 | Phase I - Functionalization of compounds |
| reactome | R-HSA-211981 | Xenobiotics |
| reactome | R-HSA-211999 | CYP2E1 reactions |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD887 | Compound 23 citrate | 2 |
| iGMDRD188 | Piperlongumine | 4 |
| iGMDRD577 | BIX01294 | 5 |
| iGMDRD64 | Parbendazole | 2 |
| iGMDRD640 | CAY10618 | 3 |
| iGMDRD268 | Cerulenin | 1 |
| iGMDRD255 | SB225002 | 2 |
| iGMDRD802 | 4-methylfasudil | 2 |
| iGMDRD294 | Batimastat | 2 |
| iGMDRD61 | Kinetin riboside | 1 |
| iGMDRD193 | Fqi1 | 2 |
| iGMDRD639 | YK 4-279 | 2 |
| iGMDRD466 | Chaetocin | 2 |
| iGMDRD297 | Austocystin D | 3 |
| iGMDRD634 | SCHEMBL2608041 | 1 |
| iGMDRD126 | Tipifarnib | 5 |
| iGMDRD1008 | SR-II-138A | 3 |
| iGMDRD772 | BRD4770 | 1 |
| iGMDRD889 | Compound 7d-cis | 8 |
| iGMDRD781 | Sirolimus | 2 |
| iGMDRD872 | BRD7137 | 1 |
| iGMDRD871 | BRD6368 | 1 |
| iGMDRD414 | MST-312 | 1 |
| iGMDRD286 | Nsc 632839 | 1 |
| iGMDRD366 | PI-103 | 1 |
| iGMDRD329 | Merck60 | 2 |
| iGMDRD886 | Compound 1541A | 2 |
| iGMDRD322 | FK 866 | 2 |
| iGMDRD158 | NSC141540 | 2 |
| iGMDRD202 | Curcumin | 4 |
| iGMDRD289 | Parthenolide | 3 |
| iGMDRD105 | Triptolide | 8 |
| iGMDRD77 | Itraconazole | 3 |
| iGMDRD481 | Dactolisib | 1 |
| iGMDRD85 | Ursolic acid | 2 |
| iGMDRD57 | Chloropentafluorobenzene | 2 |
| iGMDRD351 | GW843682X | 4 |
| iGMDRD314 | Tanespimycin | 2 |
| iGMDRD698 | Neratinib | 1 |
| iGMDRD177 | Teniposide | 1 |
| iGMDRD901 | ELCPK | 2 |
| iGMDRD945 | ML214 | 3 |
| iGMDRD486 | Tosedostat | 6 |
| iGMDRD701 | NVP-AUY922 | 2 |
| iGMDRD405 | PIK-75 | 3 |
| iGMDRD523 | Cyanoquinoline, 11 | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in CYP2B6
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.